Current Report Filing (8-k)
October 18 2022 - 1:15PM
Edgar (US Regulatory)
0001335105
false
0001335105
2022-10-13
2022-10-13
0001335105
LIXT:CommonStockParValue0.0001PerShareMember
2022-10-13
2022-10-13
0001335105
LIXT:WarrantsToPurchaseCommonStockParValue0.0001PerShareMember
2022-10-13
2022-10-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): October 13, 2022
LIXTE
BIOTECHNOLOGY HOLDINGS, INC.
(Exact
name of registrant as specified in its charter)
delaware |
|
001-39717 |
|
20-2903526 |
(State
or other jurisdiction of incorporation) |
|
(Commission
File
Number) |
|
(I.R.S.
Employer
Identification
Number) |
680
East Colorado Boulevard, Suite 180
Pasadena,
California 91101
(Address
of principal executive offices)
(631)
830-7092
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (See General Instruction A.2. below):
☐ |
Written
communications pursuant to Rule 425 under the Securities Act of 1933 (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(e) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of Each Class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, par value $0.0001 per share |
|
LIXT |
|
The
NASDAQ Stock Market, LLC |
Warrants
to Purchase Common Stock, par value $0.0001 per share |
|
LIXTW |
|
The
NASDAQ Stock Market, LLC |
On
October 13, 2022, the Company issued a press release regarding approval of a Phase 1b/2 randomized trial of doxorubicin +/-lb-100 in
advanced soft tissue sarcomas to be conducted by the Spanish Sarcoma Group.
Item
9.01. |
Financial
Statements and Exhibits. |
(d)
There is filed as part of this report the exhibit listed on the accompanying Index to Exhibits, which exhibit is incorporated herein
by reference.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date:
October 18, 2022 |
LIXTE
BIOTECHNOLOGY HOLDINGS, INC. |
|
|
|
|
By:
|
/s/
JOHN S. KOVACH |
|
|
John
S. Kovach, Chief Executive Officer |
INDEX
TO EXHIBITS
Lixte Biotechnology (NASDAQ:LIXT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Lixte Biotechnology (NASDAQ:LIXT)
Historical Stock Chart
From Apr 2023 to Apr 2024